The relationship between chondroprotective and antiinflammatory effects of Withania somnifera root and glucosamine sulphate on human osteoarthritic cartilage in vitro

Phytotherapy Research

Volumn 22, Issue 10, 2008, Pages 1342-1348

  Sumantran, Venil N ^a   Chandwaskar, Rucha ^a   Joshi, Asavari Kulkarni ^d   Boddul, Sanjay ^a   Patwardhan, Bhushan ^b   Chopra, Arvind ^c   Wagh, Ulhas V ^a  

^a Bharati Vidyapeeth   (India)

^b UNIVERSITY OF PUNE   (India)

^c Center for Rheumatic Diseases   (India)

^d NONE

Author keywords

Antiinflammatory; Cartilage explants; Chondroprotective; Withania somnifera

Indexed keywords

GLUCOSAMINE SULFATE; GLYCOSAMINOGLYCAN; NITRIC OXIDE; WITHANIA SOMNIFERA EXTRACT;

ADULT; AGED; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CHONDROPROTECTION; CONTROLLED STUDY; DRUG ACTIVITY; EXPLANT; HUMAN; IN VITRO STUDY; OSTEOARTHRITIS; PLANT ROOT; WITHANIA SOMNIFERA;

AGED; ANTI-INFLAMMATORY AGENTS; CARTILAGE; GLUCOSAMINE; HUMANS; MIDDLE AGED; OSTEOARTHRITIS; PLANT ROOTS; WITHANIA;

WITHANIA SOMNIFERA;

EID: 55449134810     PISSN: 0951418X     EISSN: 10991573     Source Type: Journal    
DOI: 10.1002/ptr.2498     Document Type: Article

References (25)

1. Amin AR, Attur MG, Thakker GD et al. 1996. A novel mechanism of action of tetracyclines: effects on nitric oxide synthases. Proc Natl Acad Sci USA 93: 14014-14019.
2. Bani S, Gautam M, Sheikh FA et al. 2006. Selective Th1 up-regulating activity of Withania somnifera aqueous extract in an experimental system using flow cytometry. J Ethnopharmacol 107: 107-115.
3. Cai L, Suboc P, Hogue DA, Ffei DT, Filvaroff EH. 2002. Interleukin 17 induced nitric oxide suppresses matrix synthesis and protects cartilage from matrix breakdown. J Rheumatol 29: 1725-1736.
4. Cibere J, Kopec JA, Thorne A et al. 2004. Randomized, double-blind, placebo-controlled glucosamine discontinuation trial in knee osteoarthritis. Arthritis Rheum 51: 738-745.
5. da Camara CC, Dowless GV 1998. Glucosamine sulfate for osteoarthritis. Ann Pharmacother 32: 580-587.
6. Dingle JT. 1991. Cartilage maintenance in osteoarthritis: interaction of cytokines, NSAID and prostaglandins in articular cartilage damage and repair. Rheumatol Suppl 28: 30-37.
7. Dingle JT. 1999. The effects of NSAID on the matrix of human articular cartilages. Z Rheumatol 58: 125-129.
8. Dodge GR, Jimenez SA. 2003. Glucosamine sulfate modulates the levels of the aggrecan and matrix metalloproteinase-3 synthesized by cultured human osteoarthritis articular chondrocytes. Osteoarthritis Cartilage 11: 424-432.
9. Fajardo M, Di Cesare PE. 2005. Disease-modifying therapies for osteoarthritis: current status. Drugs Aging 22: 141-161.
10. Ganju L, Karan D, Chanda S, Srivastava KK, Sawhney RC, Selvamurthy W. 2003. Immunomodulatory effects of agents of plant origin. Biomed Pharmacother 57: 296-300.
11. Hoemann CD, Sun J, Chrzanowski V, Bushman MD. 2002. A multivalent assay to detect glycosaminoglycan, protein, collagen, RNA, and DNA content in milligram samples of cartilage or hydrogel-based repair cartilage. Anal Biochem 300: 1-10.
12. Ismaiel S, Atkins RM, Pearse MF, Dieppe PA, Elson CJ. 1992. Susceptibility of normal and arthritic human articular cartilage to degradative stimuli. Br J Rheumatol 31: 369-373.
13. Jouzeau JY, Pacquelet S, Boileau C et al. 2002. Nitric oxide (NO) and cartilage metabolism: NO effects are modulated by superoxide in response to IL-1. Biorheology 39: 201-214.
14. Lee GM, Tioran ME, Jansen M, Graff RD, Kelley SS, Lin P. 2002. Development of selective tolerance to interleukin-1beta by human chondrocytes in vitro. J. Cell Physiol 192: 113-124.
15. Loeser RF, Carlson CS, Del Carlo M, Cole A. 2002. Detection of nitrotyrosine in aging and osteoarthritic cartilage: Correlation of oxidative damage with presence of IL-1 beta and to chondrocyte resistance to insulin-like growth factor 1. Arthritis Rheumatism 46: 2349-2357.
16. Mathy-Hartert M, Deby-Dupont GP, Reginster JY, Ayache N, Pujol JP, Henrotin YE. 2002. Regulation by reactive oxygen species of interleukin-1beta, nitric oxide and prostaglandin E(2) production by human chondrocytes. Osteoarthritis Cartilage 10: 547-555.
17. Mishra LC, Singh BB, Dagenais S. 2000. Scientific basis for the therapeutic use of Withania somnifera (ashwagandha): a review. Altern Med Rev 5: 334-346.
18. Nakamura H, Shibakawa A, Tanaka M, Kato T, Nishioka K. 2004. Effects of glucosamine hydrochloride on the production of prostaglandin E2, nitric oxide and metalloproteases by chondrocytes and synoviocytes in osteoarthritis. Clin Exp Rheumatol 22: 293-299.
19. Nethery A, Giles I, Jenkins K, Jackson C, Brooks P, Burkhardt D, Ghosh P, Whitelock J, O?Grady RL, Welgus HG et al. 1992. The chondroprotective drugs, Arteparon and sodium pentosan polysulphate, increase collagenase activity and inhibit stromelysin activity in vitro. Biochem Pharmacol. 44(8): 1549-1553.
20. NIH Glucosamine and Chondroitin Arthritis Intervention (GAIT) trial. NCCAM Publication No. D310. Updated: February 2006.
21. Outerbridge RE. 1961. The etiology of chondromalacia patellae. J Bone Joint Surg 43B: 752-757.
22. Pelletier JP, Mineau F, Ranger P, Tardif G, Martel-Pelletier J. 1996. The increased synthesis of inducible nitric oxide inhibits IL-1ra synthesis by human articular chondrocytes: possible role in osteoarthritic cartilage degradation. Osteoarthrits Cartilage 4: 77-84.
23. Pipierno M, Reboul P, Graverand HL et al. 2000. Glucosamine sulfate modulates dysregulated activities of human osteoarthritic chondrocytes in vitro. Osteoarthritis Cartilage 8: 207-212.
24. Sumantran VN, Kulkarni A, Boddul S et al. 2007a. Chondroprotective potential of root extracts of Withania somnifera in osteoarthritis. J Biosci 32: 299-307.
25. Sumantran VN, Kulkarni A, Chandwasjkar R et al. 2007b. Chondroprotective potential of fruit extracts of Phyllanthus emblica in osteoarthritis. Evid Based Complem Altern Med April 2007. DOI: 10.1093/ecam/nem030